

Risk Factors of SARS-CoV-2 and Follow-up in Patients with Common Underlying Diseases on the Dynamic Changes of Antibodies: A Cross-sectional Study

Jin Yang

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College

Libing Ma

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College

Li Guo

Key Laboratory of Respiratory Disease Pathogenomics, Chinese Academy of Medical Sciences and Peking Union Medical College

Ting Zhang

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College

Zhiwei Leng

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College

Mengmeng Jia

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College

Fangyuan Chen

Public Responsibility in Medicine and Research

Weiran Qi

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College

Xingxing Zhang

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College

Qing Wang

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College

Yuan Yang

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College

Luzhao Feng

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College

Lili Ren

Key Laboratory of Respiratory Disease Pathogenomics, Chinese Academy of Medical Sciences and Peking Union Medical College

Weizhong Yang (✉ yangweizhong@cams.cn)

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College

Chen Wang

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College

Research

Keywords: COVID-19, SARS-CoV-2, underlying diseases, antibody, longitudinal, cross-sectional study

Posted Date: October 19th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-961631/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Assessing the humoral immunity of patients with underlying diseases after being infected with SARS-CoV-2 is essential for determining effective prevention and control strategies. The purpose of this study is to investigate whether underlying disease is a risk factor for SARS-CoV-2 infection, reveal the seroprevalence of people with underlying disease and the characteristics of dynamic changes in anti-SARS-CoV-2 antibodies, and provide evidence for the scientific formulation of COVID-19 vaccination strategies.

Methods: The probability ratio sampling method was adopted to systematically select 100 communities from 13 districts in Wuhan, China, followed by a random selection of households from 100 communities according to a list provided by the local government. Individuals who have lived in Wuhan for at least 14 days since December 2019 and were ≥ 40 years old were included. Individuals with other serious diseases besides COVID-19, from whom a sample could not be obtained or refused to participate, were excluded. All eligible subjects signed a written informed consent form and completed a standardized electronic questionnaire before being enrolled in the group. From April 9–13, 2020, venous blood samples were collected from all individuals; from June 11–13, 2020, and from October 9–December 5, 2020, all positive and matched negative families were followed up.

Results: The seroprevalence of SARS-CoV-2 in people with underlying diseases was 6.30% (95% CI [5.09-7.52]), and that of people without underlying diseases was 6.12% (95% CI [5.33-6.91]). Among people with underlying diseases, retirees, health workers, and people who have been exposed to fever or respiratory symptoms since December 2019 were more likely to be infected with SARS-CoV-2. The IgG titer of people with underlying disease decreased significantly over time ($P < 0.05$), but the neutralizing antibody titer remained relatively stable throughout the follow-up period. There was no significant difference between the IgG titer decline rate of people with underlying disease and those without. The IgG titer of people with underlying disease and asymptomatic infection was lower than that in symptomatic infection.

Conclusion: These findings imply that vaccination strategies for people with and without underlying diseases may not require special adjustments.

Background

The COVID-19 global pandemic that started in 2019 is the most extensive to afflict humanity in a century. It is a serious health crisis and challenge worldwide. Some studies have shown that the risk of severe COVID-19 is higher in elderly people than in the general population because most of them have underlying diseases, such as hypertension, diabetes, and cardiovascular and cerebrovascular diseases.[1, 2] A study published in BMJ that analyzed 113 deaths and 161 patients diagnosed with COVID-19, showed that 63% of the dead and 39% of the recovered patients had at least one underlying chronic disease.[3] The results of another study published by the Lancet, in which severe COVID-19 patients in

two hospitals in the United States were analyzed, showed that more than 80% of the patients had at least one chronic disease, of which hypertension and diabetes were most common.[4] With the spread of COVID-19 in countries around the world, the mutation of virus strains, and the development and application of vaccines, assessing the proportion of the infected and immunized populations with or without underlying diseases is essential to determine effective prevention and control strategies with the ultimate goal of preventing the epidemic from continued expansion.[5–7] In a previous study, we analyzed the dynamic changes of seroprevalence and humoral immune response after natural infection with COVID-19 in Wuhan.[6] However, an in-depth study on patients with underlying diseases was lacking. The purpose of this study is to investigate whether the underlying disease is a risk factor for SARS-CoV-2 infection, the seroprevalence of people with underlying disease, and the characteristics of dynamic changes in anti-SARS-CoV-2 antibodies.

Methods

Study design and participants

This is a population-level, longitudinal, and cross-sectional study. In this study, a multistage, population-stratified, and cluster random sampling method was adopted to recruit participants within all the 13 districts of Wuhan. First, we selected 100 communities using the probability-proportionate to-size sampling method, and then randomly selected households from 100 communities based on a list provided by the local government. Individuals who have lived in Wuhan for at least 14 days since December 2019 and were ≥ 40 years old were included. Individuals with other serious diseases besides COVID-19, such as patients with advanced cancer and severe mental illness, from whom a sample could not be obtained or refused to participate were excluded.

Confirmed COVID-19 cases were defined as diagnosed with SARS-CoV-2 by quantitative PCR and CT scan of the lung. Symptomatic infection was defined as self-reported fever or respiratory symptoms and positive SARS-CoV-2 antibodies. Positive SARS-CoV-2 antibodies since December 1, 2019, and no self-reported relevant symptoms were applied as the definition of asymptomatic infection. Positive family was defined as family members of one or more participants with positive SARS-CoV-2 antibodies at baseline. The definition of a negative family: lived next door to a positive family, and all family members were negative for SARS-CoV-2 antibodies. People with at least one underlying disease were classified as people with underlying diseases, such as lung diseases (asthma, COPD, pulmonary heart disease, pulmonary fibrosis, etc.), hypertension, diabetes, and cardiovascular and cerebrovascular diseases, chronic kidney disease, chronic liver disease, tumor, immunodeficiency diseases, etc.

From April 9–13, 2020, community staff invited all family members of selected families to the community healthcare center for investigation in batches by going door-to-door or telephone. The participants signed a written informed consent form after fully understanding the content and significance of the survey. If the participant was illiterate or unable to sign, it could be signed by someone else with the participant's consent. All participants completed a standardized electronic questionnaire

simultaneously. The trained investigators collected the participants' basic information, basic medical history, contacts and exposure during the COVID-19 epidemic, onset and outcome, and other information. Finally, 5ml of venous blood was collected from all participants. During the period from June 11–13, 2020, and from October 9–December 5, 2020, all family members of a positive family and matched negative families were followed up twice. Similarly, the trained investigators also asked and collected the information of the participants.

Procedures

Serum samples were separated in the Wuhan Center for Disease Control & Prevention laboratory within 8 hours after collecting the blood samples. All laboratory tests on the blood samples were performed at the Christophe Mériex Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College in Beijing, China. All serum samples were inactivated at 56°C for 30 minutes before use, and recombinant N protein was used as the detection antigen. The electrochemiluminescence immunoassay (ECLIA) (Roche Diagnostics, Rotkreuz, Switzerland) kit was used to detect total antibodies before antibody typing. The ELISA method was used to detect titers of IgA, IgM, and IgG antibodies against the SARS-CoV-2-N protein in serum. The multifunctional microplate reader SpectraMax M5 (Molecular Devices, Sunnyvale, CA) was used to measure the optical density at 450 nm (OD_{450}). The cutoff value for IgG, IgA, and IgM were determined to be 0.10, 0.20, and 0.30, respectively, by calculating the average OD_{450} value of negative serum samples plus 3 times the standard deviation value. The ECLIA and ELISA methods were further validated with other serum samples. In-house microneutralization assays were used to detect neutralizing antibodies. The Reed-Muench method was used to calculate the neutralizing antibody titers, of which 1:8 was defined as the cutoff.

Statistical analysis

Continuous variables were tested for normality. The two groups of continuous variables that were not normally distributed were compared using a nonparametric test (two independent samples). The Kruskal-Wallis nonparametric test was used for three groups of continuous variables with non-normal distribution. Categorical variables were expressed as percentages. The χ^2 test or Fisher's exact test was applied to compare categorical variables. The binary logistic regression (stepwise method) was used to investigate the influencing factors. Only statistically significant variables in the univariate logistic regression models were further analyzed in multivariate logistic regression models. All statistical tests were two-sided performed using R software and SAS software (version 9.4), and $P < 0.05$ was considered as statistically significant.

Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results

Baseline demographic and clinical characteristics

The baseline demographics and clinical characteristics of the participants can be found in Table 1. A total of 5,067 people were included in this study, of which 313 people were positive for total antibodies (positive rate 6.18% [95%, CI: 5.51-6.84]). Among them, 767 people were in the age 56–60 group, of which 63 people had positive total antibodies (positive rate 8.21%); and 827 people were in the age ≥ 66 group, of which 63 people had positive total antibodies (positive rate 7.62%). There were 2492 males, of which 124 had positive total antibodies (positive rate 4.98%), and 2575 females, of which 189 had positive total antibodies (positive rate 7.34%). There were 1,476 retirees, of which 138 have positive total antibodies (the highest positive rate of 9.35%) and a total of 38 health workers, of which 3 had positive total antibodies (positive rate 7.89%). There were 4875 people who self-reported no symptoms, of which 248 were asymptomatic (positive rate 5.09%) and 192 people who self-reported that they had symptoms, of which 65 were symptomatic (positive rate 33.85%). There were 3528 people without underlying disease, of which 216 had positive total antibodies (positive rate 6.12%, 95%, CI:5.33-6.91), and there were 1539 people with underlying disease, of which 97 had positive total antibodies (positive rate 6.30%, 95%, CI: 5.09-7.52).

Table 1

Baseline demographics and positive rate of total antibodies of study subjects

Analysis of risk factors of SARS-CoV-2 infection

We used logistic regression (stepwise regression) to analyze the people with underlying disease. The results show that retirees (vs. other occupations, OR=2.71, 95%, CI: 1.40-5.26), health workers (vs. other occupations, OR=17.76, 95%, CI: 3.32-94.95), people who have been exposed to fever or respiratory symptoms since December 2019 (vs people who have not been exposed, OR=5.78, 95%, CI: 2.99-11.18) were more likely to be infected with SARS-CoV-2, as shown in Supplementary Table S1.

Dynamic changes of antibodies over time

A total of 313 people were positive for total antibodies at baseline, of which 216 had no underlying disease and 97 had underlying disease. At the first follow-up, a total of 212 people were positive for total antibodies, of which 146 had no underlying disease and 66 had underlying disease. At the second follow-

Variables	Number of population (%)	Number of positive total antibody (%)	95% CI	<i>P</i> -value
Total	5067 (100%)	313 (6.18%)	5.51-6.84	
Age (years)				
40-45	1072 (21.16%)	57 (5.32%)	3.97-6.67	0.02
46-50	924 (18.24%)	48 (5.19%)	3.76-6.63	
51-55	737 (14.55%)	45 (6.11%)	4.37-7.84	
56-60	767 (15.14%)	63 (8.21%)	6.27-11.02	
61-65	740 (14.60%)	37 (5.00%)	3.43-6.57	
≥66	827 (16.32%)	63 (7.62%)	5.81-9.43	
Sex				
Male	2492 (49.18%)	124 (4.98%)	4.12-5.83	<0.001
Female	2575 (50.82%)	189 (7.34%)	6.33-8.35	
Occupation				
Commercial service personal	546 (10.78%)	28 (5.13%)	3.27-6.98	<0.001
Workmen/farmers	1270 (25.06%)	40 (3.15%)	2.19-4.11	
Others	1312 (25.89%)	87 (6.63%)	5.28-7.98	
Community workers	425 (8.39%)	17 (4.00%)	2.13-5.87	
Retirees	1476 (29.13%)	138 (9.35%)	7.86-11.08	
Health workers	38 (0.75%)	3 (7.89%)	0.00-1.69	
Smoke				
No	3392	240 (7.08%)	6.21-	<0.001

	(66.94%)		7.94	
Yes	1446 (28.54%)	53 (3.67%)	2.70- 4.64	
Ever smoked	229 (4.52%)	20 (8.73%)	5.05- 1.24	
Self-reported symptom				
No	4875 (96.21%)	248 (5.09%)	4.47- 5.70	<0.001
Yes	192 (3.79%)	65 (33.85%)	27.10- 40.61	
To the hospital for fever or respiratory symptoms since December 2019				
No	4946 (97.61%)	258 (5.22%)	4.60- 5.84	<0.001
Yes	121 (2.39%)	55 (45.45%)	36.45- 54.45	
Contact with anyone with fever or respiratory symptoms since December 2019				
No	4821 (95.15%)	262 (5.43%)	4.79- 6.07	<0.001
Yes	246 (4.85%)	51 (20.73%)	15.63- 25.83	
Contact with a SARS-CoV-2 confirmed case since December 2019				
No	4922 (97.14%)	280 (5.69%)	5.04- 6.34	<0.001
Yes	145 (2.86%)	33 (22.76%)	15.85- 29.66	
Underlying disease				
No	3528 (69.63%)	216 (6.12%)	5.33- 6.91	0.81
Yes	1539 (30.37%)	97 (6.30%)	5.09- 7.52	

Notes: Underlying diseases defined as: at least one disease, such as hypertension, pulmonary disease, cancer (undergoing chemotherapy), diabetes, cardiovascular disease, chronic kidney disease, chronic liver disease, and immunodeficiency disease, among others. Workers are men employed to do manual labor.

up, a total of 238 people were positive for total antibodies, 170 of whom had no underlying disease and

68 had underlying disease. Regardless of whether underlying disease was present, the positive rate of IgA and IgM declined rapidly over time. In people with no underlying disease, the proportion of positive neutralizing antibodies increased over time. In people with underlying disease, the proportion of positive neutralizing antibodies increased from baseline to the first follow-up, while it decreased slightly during the period from the first follow-up to the second follow-up (Table 2).

Table 2

When the total antibody is positive, the change in the number of IgA, IgM, IgG, Nabs positive patients with and without underlying disease

Total antibody positive population (No.)	Underlying disease or not (No.)	IgA+(%)	IgM +(%)	IgG +(%)	Nabs+ (%)
Baseline 313	No (216)	43 (19.91%)	26 (12.04%)	216 (100.00%)	92 (42.59%)
	Yes (97)	22 (22.68%)	7 (7.22%)	97 (100.00%)	43 (44.33%)
First follow-up 212	No (146)	16 (10.96%)	4 (2.74%)	145 (99.32%)	67 (45.89%)
	Yes (66)	11 (16.67%)	1 (1.52%)	66 (100.00%)	35 (53.03%)
Second follow-up 238	No (170)	11 (6.47%)	3 (1.76%)	168 (98.82%)	88 (51.76%)
	Yes (68)	6 (8.82%)	1 (1.47%)	63 (92.65%)	36 (52.94%)

Notes: Nabs, neutralising antibody titres.

There were 219 participants with three consecutive serum samples with positive total antibodies at baseline, of which 154 had no underlying disease and 65 had underlying disease. We compared the changes in the titers of IgA, IgM, IgG, and neutralizing antibodies over time. The results showed that the IgG titers decreased significantly with or without underlying diseases and the IgA titers of people without underlying diseases decreased significantly, while the neutralizing antibody titer remained stable in people both with or without underlying disease (Figure 1).

We conducted a study on symptomatic and asymptomatic individuals, and the results showed that the proportion of IgA, IgM and IgG positive decreased gradually with the passage of time, and the proportion of neutralizing antibody positive remained stable, regardless of whether there were underlying diseases or not. (Table.3) We further compared the IgG titers of those with asymptomatic patients during the baseline, the first follow-up and the second follow-up. The results showed that in the underlying diseases group, the titer of symptomatic and asymptomatic patients at baseline and the second follow-up was different, and the titer of asymptomatic patients was lower than that of symptomatic patients (baseline, P

= 0.032, second follow-up, P = 0.018). In the no underlying diseases group, the titers of symptomatic and asymptomatic patients at baseline and the first follow-up were different, and the titers of asymptomatic patients were lower than those of symptomatic patients (baseline, P = 0.013, one follow-up, P = 0.005). (Figure.2, Supplementary Figure.1)

Table 3

When the total antibody is positive, the change in the number of symptomatic and asymptomatic positive patients with and without underlying disease

Due to the obvious downward trend of IgG, we compared the decline rate of IgG titer between people with and without underlying disease. The results showed that there was no significant difference in the decline rate of IgG titer between people with underlying diseases and those without underlying diseases (Figure 3A). A total of 65 patients with underlying diseases who had positive total antibodies at baseline and in three consecutive serum samples were divided into three groups according to the underlying disease type: simple hypertension group, hypertension combined with other diseases, and other underlying diseases group. We compared the decline rates of the IgG titers in these three groups and their results indicated no difference (Figure 3B).

Discussion

The results of this study indicate that in the case of natural infection, the seroprevalence in people ≥ 40 years of age with underlying diseases in Wuhan was 6.30% (95% CI [5.09-7.52]), while it was 6.12% in people without underlying diseases (95% CI [5.33-6.91]), suggesting that the common underlying diseases as previously mentioned had no significant effect on the positive antibody conversion rate ($P > 0.05$). There were 219 participants who had three consecutive serum samples. Regardless of whether underlying disease was present, the IgG titer decreased significantly over time, and the neutralizing antibody titer remained relatively stable within the 9 months. There was no significant difference in the decline rate of IgG between people with and without underlying diseases. In patients with underlying diseases, the mean IgG titers of asymptomatic infections at the second follow-up were still lower than those of symptomatic infections, suggesting that the presence or absence of symptoms after infection is related to the intensity of immune efficacy.

There have been a few studies on underlying diseases and SARS-CoV-2. These studies have proven that underlying disease is a risk factor for severe disease, but it is unknown whether they are risk factors for SARS-CoV-2 infection. Our study is the first serological study of dynamic follow-up of people 40 years of age and older with underlying diseases and in a state of natural infection. We continued to follow up on the rate of positive antibodies and their dynamic changes within the 9 months. At the same time, we also conducted tests on participants' antiviral immunoglobulin and neutralizing antibodies, comprehensively assessed the immune response and efficacy, and improved understanding of the seroconversion of

Total antibody positive (No.)	Underlying disease (No.)	IgA+(%)	IgM +(%)	IgG +(%)	Nabs+(%)
Baseline					
Symptomatic (65)	Yes (23)	5 (21.74%)	0 (0.00%)	23 (100.00%)	14 (60.87%)
	No (42)	7 (16.67%)	3 (7.14%)	42 (100.00%)	24 (57.14%)
Asymptomatic (248)	Yes (74)	17 (22.97%)	7 (9.46%)	74 (100.00%)	29 (39.19%)
	No (174)	36 (20.69%)	23 (13.22%)	174 (100.00%)	68 (39.08%)
First follow-up					
Symptomatic (56)	Yes (20)	3 (15.00%)	0 (0.00%)	20 (100.00%)	15 (75.00%)
	No (36)	3 (8.33%)	1 (2.78%)	36 (100.00%)	22 (61.11%)
Asymptomatic (156)	Yes (46)	8 (17.39%)	1 (2.17%)	46 (100.00%)	20 (43.48%)
	No (110)	13 (11.82%)	3 (2.73%)	109 (99.09%)	45 (40.91%)
Second follow-up					
Symptomatic (60)	Yes (20)	0 (0.00%)	0 (0.00%)	19 (95.00%)	13 (65.00%)
	No (40)	0 (0.00%)	0 (0.00%)	39 (97.50%)	27 (67.50%)
Asymptomatic (178)	Yes (48)	6 (12.50%)	1 (2.08%)	44 (91.67%)	23 (47.92%)
	No (130)	11 (8.46%)	3 (2.31%)	129 (99.23%)	61 (46.92%)

Nabs, neutralising antibody titres

people with underlying diseases after natural infection with SARS-CoV-2. To the best of our knowledge, there are few long-term studies with such large samples of people with natural infections and all-round testing of participants' antiviral immunoglobulins and neutralizing antibodies simultaneously. In this way, it is possible to evaluate the characteristics of the immune response to SARS-CoV-2 infection in the common underlying disease population more objectively.

We also used logistic regression (stepwise regression) regulations to avoid the collinearity problem between various factors. After adjustment, the risk of SARS-CoV-2 infection in retirees was 2.71 times

that of other occupations in the group with underlying diseases, which may be related to the fact that most retirees are elderly. Wei-Jie Guan et al. conducted a study of 1,590 confirmed COVID-19 patients with an average age of nearly 50 years in 575 hospitals in 31 provinces, autonomous regions, and municipalities in mainland China.[8] The results showed that COVID-19 patients with at least one comorbidity were associated with higher severity of the disease.[8] Complications mainly included hypertension, diabetes, cerebrovascular disease, and chronic obstructive pulmonary disease. These results align with our research, suggesting that retirees with underlying disease were at higher risk of infection. As a special population, health workers have higher exposure risks and were more likely to be infected with SARS-CoV-2 (OR=17.76, 95%, CI: 3.32-94.95). The confidence interval range was larger because the number of qualified medical personnel included in the statistical analysis was small. However, it still provided a certain amount of practical reference value. In a cross-sectional study from the Lombardy region in Italy, IgG serological testing was conducted on health workers from April 1 to May 26, 2020.[9] The results showed that some professionals accustomed to managing infectious diseases had a higher risk of SARS-CoV-2 infection.[9] This is related to the repeated exposure of health workers to COVID-19 patients. One should be reminded that attention must be paid to the personal protection of key populations to reduce the risk of infection in the occupational environment, including current immigration management and related staff. People who have been exposed to fever or respiratory symptoms since December 2019 are more susceptible to SARS-CoV-2 infection because these people were more likely to be exposed to SARS-CoV-2.

Similar to SARS-CoV and the Middle East Respiratory Syndrome Coronavirus (MERS-COV), SARS-CoV-2 infection can stimulate the humoral immune response.[10–12] Understanding the positive rate of antibodies on a population-level and the dynamic characteristics of humoral immunity is critical to formulating vaccination strategies, especially for middle-aged and elderly people with common underlying diseases. The key to controlling COVID-19 is the development of effective vaccines.[13] Although a variety of effective vaccines are currently available in China, such as inactivated vaccines, adenovirus vector vaccines, subunit recombinant protein vaccines, etc., for a large number of middle-aged and elderly people with underlying diseases, the task of vaccination is still arduous, in which the scientific formulation of vaccination strategies and procedures is especially important. Therefore, it is essential to further detect IgG antibodies and neutralizing antibodies of SARS-CoV-2 to assess the dynamic changes in the attenuation of the immune function in patients with underlying disease over a long period of time.

In our study, the positive conversion rate of neutralizing antibodies of people with underlying diseases was higher than that of those without underlying diseases at each stage of the test. In people with and without underlying diseases, we have observed that the positive conversion rate of neutralizing antibodies in symptomatic patients at all stages was higher than that of asymptomatic patients. This result may be related to patients with underlying diseases being more likely to be infected with SARS-CoV-2 and become symptomatic infections.[14, 15]

The neutralizing antibody response helps to prevent reinfection with the virus.[16, 17] A study in Iceland showed that the total antibody titer did not decrease significantly within 4 months after the infection was

confirmed.[18] A study by Cesheng Li et al. included 869 patients who recovered from natural infections in Wuhan, from whom 1782 plasma samples were collected and analyzed.[16] The results showed that more than 70% of plasma donors could continue to produce detectable receptor-binding domain (RBD)-IgG for more than 1 year after diagnosis.[19] Our research found that the IgG titer decreased significantly regardless of the underlying disease, while the neutralizing antibody titer remained stable within the 9 months. Regardless of whether the antibody-positive patients had symptoms, the neutralizing antibody titer did not decrease significantly during the study period in either group (underlying disease and non-underlying disease), suggesting that it may be unnecessary to differentiate between these two groups of people in the future vaccination process.

Some studies have also performed a linear fit of antibody titers. However, there is currently no study comparing the decline rate of IgG titers in positive patients with different underlying diseases. Therefore, we compared the decline rate of IgG in people with and without underlying diseases. The IgG titer of people with underlying disease declined slightly, but there was no difference between the regression coefficients of the two groups. Therefore, the immune protection after receiving vaccination may not have a significant impact, and there is no need to formulate a special immunization program for people with underlying diseases.

We conducted a study on symptomatic and asymptomatic patients. Regardless of whether the two groups had underlying diseases, the proportion of people positive for IgA, IgM, and IgG gradually decreased over time, while the ratio of neutralizing antibodies was relatively stable. Combined with the results of our previous studies, it indicates that asymptomatic infections in the real world will likely be an important part of the immune population. Therefore, a scientific and objective understanding of their antibody levels and changes is critical for formulating future vaccination strategies and procedures for such populations. It is also the key to preventing the continuous spread of the COVID-19 pandemic and the continuous mutation of the virus as soon as possible.

The constant mutation of the virus has caused concern worldwide because it may spread more quickly, and the effectiveness of vaccines against these mutated viruses may also be reduced, especially for middle-aged and elderly people with underlying diseases.[20] A Danish study showed that previous infections could only provide 47% protection in people 65 years of age and older, indicating that the elderly are more likely to be infected with COVID-19 again.[21] An Israeli study showed that, including the elderly, two doses of Pfizer's BioNTech COVID-19 vaccine have a 95% protection rate against infection, hospitalization, severe illness, and death.[22] However, as elderly are the main population of basic diseases, studies on whether different vaccination strategies should be formulated to improve the effectiveness of protection have been lacking. Our research suggests that as long as the vaccination conditions are met, the presence or absence of underlying diseases will not significantly affect post-vaccination immunity and effectiveness. In any case, taking personal protective measures, maintaining a safe social distance, and vaccinating as soon as possible are still the most reliable prevention and control measures in the context of the continuing COVID-19 pandemic.

This study also has certain limitations. Firstly, some symptomatic patients reported that they had symptoms, in which case recall bias may have occurred. Secondly, after the Wuhan lockdown, we followed up with the patients, but there were quite a few asymptomatic people with infection, and we could not determine the time of their initial infection. Finally, since more than half of the infected people in mainland China are concentrated in Wuhan, the extrapolation of the results may be limited, although this limitation is likely small.

Conclusion

In sum, our research focused on the serological study of people with underlying diseases and in a state of natural infection. The positive rate of antibodies in people aged 40 and above with underlying diseases was similar to those without underlying diseases. Regardless of the underlying disease, the IgG titer decreased significantly over time, while there was no significant difference in the decline rate of IgG between the two groups; and the neutralizing antibody titer remained relatively stable within the 9 months. Regardless of the presence or absence of underlying disease, the mean IgG titer was lower in asymptomatic patients with infection than in symptomatic patients. Based on our research results, it may be helpful to focus on speeding up the implementation of vaccinations in elderly. Under the current epidemic situation, it is necessary to mobilize and complete the vaccination strategy of middle-aged and elderly people with a stable stage of underlying diseases and no obvious contraindications as soon as possible as this group will potentially be the largest beneficiaries of vaccination. However, there is still a need for more targeted scientific research on the issue whether the population will need booster vaccines in the future and how to inoculate, including the specific vaccination time slot and when the neutralizing antibody drops to the most appropriate value.

Abbreviations

ECLIA : electrochemiluminescence immunoassay

ELISA: enzyme linked immunosorbent assay

OD₄₅: optical density at 450 nm

CI: confidence interval

OR: odds ratio

Declarations

Ethics approval and consent to participate

This study was approved by the Ethical Review Board of the Institute of Pathogen Biology, Chinese Academy of Medical Sciences (IPB-2020-04).

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors have no competing interests to declare

Funding

This study was funded by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (2020-I2M-1-001, 2020-I2M-2-015, 2016-I2M-1-014), National Natural Science Foundation (82041031), Non-profit Central Research Institute Fund of CAMS (2019PT310029), and the National Major Science & Technology Project for Control and Prevention of Major Infectious Diseases in China (2017ZX10103004, 2017ZX10204401).

Authors' contributions

WC, YWZ, and RLL contributed to the study design and methods. GL and RLL did the laboratory analyses. LZW, JMM, CFY, QWR and ZXX collected data. YJ, MLB and ZT were analyzed and interpreted the patient data. WQ and YY checked the data results. YJ wrote the manuscript and subsequent versions. YWZ and FLZ provided overall guidance. All authors read and approved the final manuscript.

Acknowledgments

We thank all the individuals who generously shared their time and materials for this study. We thank the clinicians who contributed to sample collection and transportation.

References

1. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. *Lancet Glob Health*. 2020;8:e1003-e17. doi:10.1016/S2214-109X(20)30264-3.

2. Landstra CP, de Koning EJP. COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course. *Front Endocrinol (Lausanne)*. 2021;12:649525. doi:10.3389/fendo.2021.649525.
3. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ*. 2020;368:m1091. doi:10.1136/bmj.m1091.
4. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet*. 2020;395:1763–70. doi:10.1016/S0140-6736(20)31189-2.
5. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *Lancet*. 2020;396:535–44. doi:10.1016/S0140-6736(20)31483-5.
6. He Z, Ren L, Yang J, Guo L, Feng L, Ma C, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. *Lancet*. 2021;397:1075–84. doi:10.1016/S0140-6736(21)00238-5.
7. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet*. 2020;396:313–9. doi:10.1016/S0140-6736(20)31304-0.
8. Guan W-J, Liang W-H, Zhao Y, Liang H-R, Chen Z-S, Li Y-M, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J*. 2020, 55. doi:10.1183/13993003.00547-2020.
9. Poletti P, Tirani M, Cereda D, Guzzetta G, Trentini F, Marziano V, et al. Seroprevalence of and Risk Factors Associated With SARS-CoV-2 Infection in Health Care Workers During the Early COVID-19 Pandemic in Italy. *JAMA Netw Open*. 2021;4:e2115699. doi:10.1001/jamanetworkopen.2021.15699.
10. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. *Nat Commun*. 2020;11:4704. doi:10.1038/s41467-020-18450-4.
11. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to experimental coronavirus infection of man. *Epidemiol Infect*. 1990;105:435–46.
12. Mo H, Zeng G, Ren X, Li H, Ke C, Tan Y, et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. *Respirology*. 2006;11:49–53.
13. Sariol A, Perlman S. Lessons for COVID-19 Immunity from Other Coronavirus Infections. *Immunity*. 2020;53:248–63. doi:10.1016/j.immuni.2020.07.005.
14. Deravi N, Fathi M, Vakili K, Yaghoobpoor S, Pirzadeh M, Mokhtari M, et al. SARS-CoV-2 infection in patients with diabetes mellitus and hypertension: a systematic review. *Rev Cardiovasc Med*. 2020;21:385–97. doi:10.31083/j.rcm.2020.03.78.
15. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323:1239–42. doi:10.1001/jama.2020.2648.

16. Li C, Yu D, Wu X, Liang H, Zhou Z, Xie Y, et al. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan. *Nat Commun.* 2021;12:4144. doi:10.1038/s41467-021-24230-5.
17. Dörner T, Radbruch A. Antibodies and B cell memory in viral immunity. *Immunity.* 2007;27:384–92.
18. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. *N Engl J Med.* 2020;383:1724–34. doi:10.1056/NEJMoa2026116.
19. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature.* 2020;584:430–6. doi:10.1038/s41586-020-2521-4.
20. Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. *Lancet Public Health.* 2021;6:e335-e45. doi:10.1016/S2468-2667(21)00055-4.
21. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. *Lancet.* 2021;397:1204–12. doi:10.1016/S0140-6736(21)00575-4.
22. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet.* 2021;397:1819–29. doi:10.1016/S0140-6736(21)00947-8.

Figures




Figure 2

Comparison of antibody titers of symptomatic patients and asymptomatic patients among 219 subjects with positive total antibodies at baseline and three consecutive serum samples Note: Longitudinal changes in IgG of underlying disease group and no underlying disease group.




Figure 3

Comparison of the decline rate in IgG antibody titer among the 219 subjects with positive total antibodies at baseline and three consecutive serum samples A: Comparison of the decline rate between underlying diseases and no underlying diseases. B: A total of 65 people in the basic disease group were positive for antibodies at baseline and three consecutive samples. Comparison of the following three groups: hypertension group, hypertension combined with other diseases group, and other basic diseases group. **: $P < 0.01$; ***: $P < 0.001$; ns: no significance

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupFig.1.tif](#)
- [Supplementary.docx](#)